Sirtuins在乳腺癌中作用机制的研究进展

doi:10.11904/j.issn.1002-3070.2021.03.016

Abstract

Abstract: Breast cancer is one of the most common malignant tumors in women.The two major factors leading to its related deaths are recurrence,metastasis and multidrug resistance(MDR).Sirtuins family proteins are a class of NAD+-dependent deacetylases,which play an important role in various biological processes and diseases,and are related to the occurrence and development ofbreast cancer and MDR.It is very important to grasp the mechanism of Sirtuins in Breast cancer.Therefore,this article summarizes the role of Sirtuins in breast cancer,discusses the mechanism of each subtype of Sirtuins family on the occurrence and development of breast cancer and MDR,and summarizes the current research progress of Sirtuins related drugs.

Key words: Breast cancer, SIRTs, Multidrug resistance

CLC Number:

R737.9

LI Yuying, ZHANG Yue. Research progress of Sirtuins in breast cancer[J]. Journal of Practical Oncology, 2021, 35(3): 277-281.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.03.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I3/277

References

1 Kim HM,Koo JS.Clinicopathologic characteristics of breast cancer according to the infiltrating immune cell subtypes[J].Int J Mol Sci,2020,21(12):4438.
2 Kalous KS,Wynia-Smith SL,Summers SB,et al.Human sirtuins are differentially sensitive to inhibition by nitrosating agents and other cysteine oxidants[J].J Biol Chem,2020,295(25):8524-8536.
3 Mautone N,Zwergel C,Mai A,et al.Sirtuin modulators:where are we now? A review of patents from 2015 to 2019[J].Expert Opin Ther Pat,2020,30(6):389-407.
4 Zahedipour F,Jamialahmadi K,Karimi G.The role of noncoding RNAs and sirtuins in cancer drug resistance[J].Eur J Pharmacol,2020,877:173094-173094.
5 He Q,Chen K,Ye R,et al.Associations of sirtuins with clinicopathological variables and prognosis in human ovarian cancer[J].Oncol Lett,2020,19(4):3278-3288.
6 Jin X,Wei Y,Xu F,et al.SIRT1 promotes formation of breast cancer through modulating Akt activity[J].J Cancer,2018,9(11):2012-2023.
7 Xu Y,Qin Q,Chen R,et al.SIRT1 promotes proliferation,migration,and invasion of breast cancer cell line MCF-7 by upregulating DNA polymerase delta1(POLD1)[J].Biochem Biophys Res Commun,2018,502(3):351-357.
8 Yue Y,He L,Tian M,et al.Construction of SIRT1 gene shRNA lentivirus vector and its effect on the proliferation of breast cancer cells[J].Cell Mol Biol(Noisy-le-grand),2020,66(3):204-210.
9 Chung SY,Jung YY,Park HS,et al.Oncogenic role of SIRT1 associated with tumor invasion,lymph node metastasis,and poor disease-free survival in triple negative breast cancer[J].Clin Exp Metastasis,2016,33(2):179-185.
10 Wu M,Wei W,Xiao X,et al.Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer[J].Medical Oncology,2012,29(5):3240-3249.
11 Shi L,Tang XL,Qian MX,et al.A SIRT1-centered circuitry regulates breast cancer stemness and metastasis[J].Oncogene,2018,37(49):6299-6315.
12 Gollavilli PN,Kanugula AK,Koyyada,et al.SAMPK inhibits MTDH expression via GSK 3β and SIRT 1 activation:potential role in triple negative breast cancer cell proliferation[J].FEBS J,2015,282(20):3970-3985.
13 McGlynn LM,Zino S,MacDonald AI,et al.SIRT2:tumour suppressor or tumour promoter in operable breast cancer?[J].Eur J Cancer,2014,50(2):290-301.
14 Shi P,Zhou M,Yang Y.Upregulated tumor sirtuin2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients[J].Irish J Med Sci,2020,189(12):83-89.
15 Zhou W,Ni TK,Wronski A,et al.The SIRT2 Deacetylase stabilizes slug to control malignancy of basal-like breast cancer[J].Cell reports,2016,17(5):1302-1317.
16 Sterneck E,Poria DK,Balamurugan K.Slug and E-cadherin:stealth accomplices?[J].Front Mol Biosci,2020,7:138.
17 He S,He C,Yuan H,et al.The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients[J].Cell Physiol Biochem,2014,34(6):2061-2069.
18 Kenny TC,Craig AJ,Villanueva A,et al.Mitohormesis primes tumor invasion and metastasis[J].Cell Reports,2019,27(8):2292-2303.
19 Neeli PK,Gollavilli PN,Mallappa S,et al.A novel metadherinΔ7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFB-SIRT3 axis[J].Oncogene,2020,39(10):2088-2102.
20 Lee JJ,Van de RAH,Zaganjor E,et al.Inhibition of epithelial cell migration and Src/FAK signaling by SIRT3[J].Proc Natl Acad Sci U S A,2018,115(27):7057-7062.
21 Shi Q,Liu T,Zhang X,et al.Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer[J].Oncology Lett,2016,12(4):2606-2612.
22 Greene KS,Lukey MJ,Wang X,et al.SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis[J].Proc Natl Acad Sci U S A,2019,116(52):26625-26632.
23 Uzelac B,Krivokuca A,Brankovic-Magic M,et al.Expression of SIRT1,SIRT3 and SIRT6 genes for predicting survival in triple-negative and hormone receptor-positive subtypes of breast cancer[J].Pathol Oncol Res,2020,26(4):2723-2731.
24 Tang X,Shi L,Xie N,et al.SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis[J].Nat Commun,2017,8(1):318.
25 Huo Q,Li Z,Cheng L,et al.SIRT7 is a prognostic biomarker associated with immune infiltration in luminal breast cancer[J].Front Oncol,2020,10:621.
26 Chen KL,Li L,Yang FX,et al.SIRT7 depletion inhibits cell proliferation,migration,and increases drug sensitivity by activating p38MAPK in breast cancer cells[J].J Cell Physiol,2018,233(9):6767-6778.
27 Tong CWS,Mingxia W,Cho WCS,et al.Recent advances in the treatment of breast cancer[J].Front Onco,2018,8:227.
28 Behzad M,Ali M,Sadaf D,et al.The different mechanisms of cancer drug resistance:a brief review[J].Adv Pharm Bull,2017,7(3):339-348.
29 Wang C,Chen L,Hou X,et al.Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage[J].Nature Cell Biology,2006,8(9):1025-1031.
30 Wang Z,Chen W.Emerging roles of SIRT1 in cancer drug resistance[J].Genes Cancer,2013,4(3/4):82-90.
31 Du ZG,Liu XJ,Chen T,et al.Targeting a Sirt5-Positive subpopulation overcomes multidrug resistance in Wild-Type Kras colorectal carcinomas[J].Cell Reports,2018,23(13):3975-3978.
32 Choi HK,Cho KB,Phuong NTT,et al.SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells.[J].Mol Pharm,2013,10(7):2517-2527.
33 Oh WK,Cho KB,Hien TT,et al.Amurensin G,a potent natural SIRT1 inhibitor,rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1[J].Mol Pharmacol,2010,78(5):855-864.
34 Kim HB,Lee SH,Um JH,et al.Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1[J].Oncotarget,2015,6(34):36202-36218.
35 Li K,Ying M,Feng D,et al.Brachyury promotes tamoxifen resistance in breast cancer by targeting SIRT1[J].Biomed Pharmacother,2016,84:28-33.
36 Jin X,Wei Y,Liu Y,et al.High Expression of SIRT1 associates with the doxorubicin resistance of Breast cancer through activating of Akt[J].Anticancer Agents Med Chem,2019,20(1):94-102.
37 Wei Y,Guo Y,Zhou J,et al.Nicotinamide overcomes doxorubicin resistance of breast cancer cells through deregulating SIRT1/Akt pathway[J].Anticancer Agents Med Chem,2019,19(5):687-696.
38 Bourguignon LY,Xia W,Wong G.Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells[J].J Biol Chem,2009,284(5):2657-2671.
39 Zhang L,Ren X,Cheng Y,et al.Identification of Sirtuin 3,a mitochondrial protein deacetylase,as a new contributor to tamoxifen resistance in breast cancer cells[J].Biochem Pharmacol,2013,86(6):726-733.
40 Sinha S,Patel S,Athar M,et al.Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer:an in silico and in vitro study[J].Int J Biol Macromol,2019,140:454-468.
41 Torrens-Mas M,Pons DG,Sastre-Serra J,et al.SIRT3 silencing sensitizes breast cancer cells to cytotoxic treatments through an increment in ROS production[J].J Cell Biochem,2017,118(2):397-406.
42 Xing J,Li J,Fu L,et al.SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL/STAT3 signal pathway[J].Cancer Medicine,2019,8(16):7086-7097.
43 Xu L,Che X,Wu Y,et al.SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer[J].Oncol Rep,2018,39(5):2315-2323.
44 Mattaka K,Yolanda O,Chun G,et al.SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer[J].Carcinogenesis,2013,34(7):1476-1486.
45 Thirumurthi U,Shen J,Xia W,et al.MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer[J].Sci Signal,2014,7(336):71.
46 Mahmud Z,Gomes AR,Lee HJ,et al.EP300 and SIRT1/6 Co-Regulate lapatinib sensitivity via modulating FOXO3-Acetylation and activity in breast cancer[J].Cancers(Basel),2019;11(8):1067.
47 Sociali G,Galeno L,Parenti MD,et al.Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics[J].Eur J Med Chem,2015,102:530-539.
48 Damonte P,Sociali G,Parenti MD,et al.SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects[J].Bioorg Med Chem,2017,25(20):5849-5858.

[1]	TI Qian, ZHANG Qingyuan. Research progress of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer [J]. Journal of Practical Oncology, 2021, 35(3): 287-290.
[2]	YANG Min, ZHANG Jiaoyan, Duan Dan, XU Binghe. Bibliometrics and visual analysis of breast cancer caregivers [J]. Journal of Practical Oncology, 2021, 35(2): 110-116.
[3]	WANG Jianyu, ZHANG Xianyu, PANG Da. Influencing factors of neoadjuvant chemotherapy for Luminal A type breast cancer [J]. Journal of Practical Oncology, 2021, 35(2): 131-136.
[4]	HU Yang, ZHANG Qingyuan. Research progress of PARP inhibitors in the treatment of BRCA1/2 mutation metastatic breast cancer [J]. Journal of Practical Oncology, 2021, 35(2): 184-187.
[5]	ZHU Yunfang,WEN Hongmei,QIN Mingfang,SHI Qingping,CHENG Huirong,GAO Jiao,CHEN Yang. Analysis on the incidence and death of female breast cancer in Yunnan cancer registration areas from 2011 to 2016 [J]. Journal of Practical Oncology, 2021, 35(1): 18-22.
[6]	NIU Ming, YU Ge. Gankyrin promotes tumor proliferation,metastasis and cancer stem cell characteristic in breast cancer [J]. Journal of Practical Oncology, 2020, 34(6): 518-523.
[7]	LIU Hong, LU Hailing, CAI Li. Advances in imaging prediction of prognosis and neoadjuvant chemotherapy response in breast cancer patients [J]. Journal of Practical Oncology, 2020, 34(6): 535-539.
[8]	YUAN Yao, ZHOU Xianli. Research progress on the correlation between ultrasound features and axillary lymph node metastasis in breast cancer [J]. Journal of Practical Oncology, 2020, 34(6): 576-580.
[9]	ZUO Tingting, WU Ying, DONG Shoulan, QU Ning, GAO Kuiran, LI Mengdan, LIU Yunyong. Analysis of breast cancer screening results in urban areas of Shenyang,Liaoning province,2016-2018 [J]. Journal of Practical Oncology, 2020, 34(5): 387-390.
[10]	GUO Piaoting, ZOU Yang. LncRNA SOX2OT sponge adsorbs miR-34a to promote SOX2 expression and enhance multidrug resistance in colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(5): 398-403.
[11]	ZHAO Rencheng, LIN Zitang, YU Weijun, LEI Lin, LIU Zheng, XU Ying, GUO Yanfang, PENG Ji. Analysis of the prevalence of five cancer risks among permanent residents aged 40~74 years old in Baoan District,Shenzhen,2017—2019 [J]. Journal of Practical Oncology, 2020, 34(4): 315-320.
[12]	TONG Xiao, XING Jiani, WANG Lihong. Long-chain noncoding RNA HCP5 promotes triple-negative breast cancer by regulating apoptotic pathway [J]. Journal of Practical Oncology, 2020, 34(4): 321-327.
[13]	LIU Siqi, BIAN Nana, SU Yajuan. Research on the value of ultrasound BI-RADS combined with serum CA15-3 and CEA in the diagnosis of breast tumors [J]. Journal of Practical Oncology, 2020, 34(4): 347-351.
[14]	ZHANG Rui, LI Zhigao. Clinical research progress of mucinous breast cancer [J]. Journal of Practical Oncology, 2020, 34(4): 377-381.
[15]	CHEN Du, QIAN Cheng. Research progress of mesenchymal cell-mediated chemotherapy resistance in tumor microenvironment of breast cancer [J]. Journal of Practical Oncology, 2020, 34(4): 382-386.

Research progress of Sirtuins in breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments